帕薩妥珠單抗
化合物
帕薩妥珠單抗（INN：parsatuzumab[1]；開發代號：MEGF0444A）是一種人源化單株抗體，設計用於治療多種癌症，包括轉移性結直腸癌和非鱗狀非小細胞肺癌。它充當免疫調節劑並與EGFL7結合。[2][3]
| 單株抗體 | |
|---|---|
| 種類 | 完整抗體 |
| 目標 | EGFL7 |
| 臨床資料 | |
| ATC碼 |
|
| 識別資訊 | |
| CAS號 | 1312797-14-0 |
| ChemSpider |
|
| UNII | |
| 化學資訊 | |
| 化學式 | C6560H10130N1758O2046S46 |
| 摩爾質量 | 147,836.22 g·mol−1 |
參考資料
- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 (PDF). WHO Drug Information. 2012, 26 (2) [2024-03-19]. （原始內容存檔 (PDF)於2016-03-04）.
- ^ García‐Carbonero, Rocío; van Cutsem, Eric; Rivera, Fernando; Jassem, Jacek; Gore, Ira; Tebbutt, Niall; Braiteh, Fadi; Argiles, Guillem; Wainberg, Zev A.; Funke, Roel; Anderson, Maria. Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer. The Oncologist. 2017-04, 22 (4) [2024-03-19]. ISSN 1083-7159. PMC 5388369
. PMID 28275117. doi:10.1634/theoncologist.2016-0133. （原始內容存檔於2024-04-22）.
- ^ von Pawel, Joachim; Spigel, David R.; Ervin, Thomas; Losonczy, György; Barlesi, Fabrice; Juhász, Erzsébet; Anderson, Maria; McCall, Bruce; Wakshull, Eric; Hegde, Priti; Ye, Weilan. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer. The Oncologist. 2018-06-01, 23 (6) [2024-03-19]. ISSN 1083-7159. PMC 6067939 . PMID 29438092. doi:10.1634/theoncologist.2017-0690. （原始內容存檔於2024-04-20） （英語）.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Parsatuzumab, American Medical Association.
